Sinutab Plus

Quick links to important sections

Sinutab Plus

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sinutab Plus

Quick Facts

Property Description
Active Ingredients Acetaminophen and Phenylephrine Hydrochloride
Form Oral Tablet (solid, fixed-dose combination)
Pharmacological Class Analgesic/Antipyretic and Sympathomimetic Decongestant
Common Use (General) Symptomatic relief of cold and flu discomforts
Origin Synthetic Compounds

What Type of Medicine is Sinutab Plus?

Sinutab Plus is defined as an Over-the-Counter (OTC) fixed-dose combination product intended for oral, systemic administration, marketed specifically for multi-symptom relief. The preparation is a synthetically derived oral tablet, placing it within the therapeutic class of Upper Respiratory Combinations. Its positioning focuses on addressing the core discomforts of the common cold and flu in a single step, intended to improve patient compliance compared to managing multiple single-ingredient products.


What is the Composition of Sinutab Plus?

The product contains two primary active ingredients [INN]: Acetaminophen and Phenylephrine Hydrochloride. Acetaminophen is widely categorized as an analgesic and antipyretic, functioning to relieve minor pain and reduce fever. This non-opioid property is a standard characteristic of the medication. Phenylephrine Hydrochloride is a sympathomimetic nasal decongestant, which acts to constrict blood vessels. This medicine provides temporary relief by helping to shrink swollen nasal passages and ease breathing. This specific combination is often found in similar formulations marketed under different names, reflecting a common pharmaceutical approach to multi-symptom cold management.


What is the General Purpose of this Combination?

The general purpose of this specific formulation is to provide multi-symptom relief by combining two different therapeutic actions in a single preparation. The dual composition is designed to simultaneously address systemic discomforts, such as elevated body temperature and generalized aches, while mitigating the functional issue of restricted airflow caused by nasal congestion. This integrated design allows the product to target both pain/fever and nasal stuffiness concurrently, providing comprehensive relief for a typical cold scenario.

Regulatory References

  1. NIH Phenylephrine Monograph (StatPearls)

What side effects are possible with Sinutab Plus?

Possible side effects and safety information

The official safety profile for the active components in Sinutab Plus (Acetaminophen/Paracetamol and Phenylephrine) is classified by frequency and the body system affected, consistent with regulatory standards.

Frequency-Classified Adverse Reactions

Adverse reactions are formally categorized in regulatory documentation, such as the Summary of Product Characteristics (SmPC) framework:

  • Very Common: Headache.
  • Common: Insomnia, Dizziness, Nervousness, Dry mouth, and Nausea.
  • Rare: Hypersensitivity, Hepatic necrosis, and Rash.
  • Not Known: Effects documented in this category include Tachycardia, Palpitations, Hypertension, Cerebrovascular accident, and severe skin reactions.

System-Organ Classes and Serious Reactions

The most frequently reported adverse effects belong to the Nervous System Disorders and Gastrointestinal Disorders classes. The regulatory labeling also specifies potential effects in Cardiac Disorders, Vascular Disorders, and Hepatobiliary Disorders.

Serious adverse reactions documented in regulatory sources include severe liver damage (associated with Acetaminophen, particularly in overdose), severe skin reactions (such as AGEP), and hypertensive crisis or cerebrovascular accident (linked to the sympathomimetic component).


Population-Specific Safety Notes

The official safety information notes specific considerations for certain patient groups:

  • Older Adults: May be more susceptible to effects like dizziness, drowsiness, confusion, and urinary retention.
  • Hepatic and Renal Impairment: Caution is advised, and the risk of overdose and liver damage is officially noted as greater in those with non-cirrhotic alcoholic liver disease.

Safety-Related Restrictions

Regulatory authorities require explicit warnings and constraints, including a Liver Warning regarding the risk of severe liver damage from taking too much Acetaminophen, and an Allergy Alert for potential severe skin reactions. Furthermore, the product is constrained from use alongside other products containing Acetaminophen or Monoamine Oxidase Inhibitors (MAOIs).

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Sinutab Plus, a combination product containing paracetamol, a decongestant, and an antihistamine, requires immediate, urgent medical evaluation due to the potential for severe, delayed toxicity.

Documented Overdose Manifestations

Initial signs of overdose, particularly from the paracetamol component, may include nausea, vomiting, stomach pain, pallor, and sweating. These early symptoms may be mild or even absent, yet severe toxicity can still progress. The decongestant and antihistamine components can contribute to acute symptoms, such as agitation, heart rate changes, or excessive drowsiness.

Critical Actions Required

Immediate medical attention must be sought in all cases of suspected overdose, even if the individual appears or feels well. Acute liver failure, which can be fatal, is the principal serious consequence associated with paracetamol overdose and often develops days after initial ingestion.

Antidotal Treatment and Monitoring

The regulatory profile mandates the prompt administration of a specific antidote, N-acetylcysteine, which is most effective when given early. Hospital management involves continuous observation, monitoring of vital signs, and frequent testing of blood levels to assess liver and kidney function and determine the necessity and duration of antidotal therapy. Special consideration is given to patients with existing liver disease or chronic alcohol consumption.

Therapeutic Uses of Sinutab Plus

Sinutab Plus is applied across domains where short-term symptomatic support is needed to address symptom clusters associated with acute episodes. This type of combination medicine is used for managing symptoms related to systemic imbalance that may accompany these episodes. Components of this product are used for the temporary relief of common symptoms like fever and minor aches.

The medication is commonly used across conditions characterized by periods of heightened symptoms that interfere with daily functioning, such as those associated with congestion. It is relevant for easing discomfort caused by symptoms like a stuffy nose, sinus pressure, fever, and minor body aches. Applying this assistance during acute episodes supports the patient during difficult episodes by easing distress. The product provides support that contributes to easing the overall symptom burden.

“This approach may assist with maintaining a sense of functional stability and provides supportive relief when symptoms interfere with routine activities.”

Quick Fact: Supports Easing Nasal Congestion

Regulatory References

  1. Health Canada Cold and Flu Labelling Standard

Eligibility and Restrictions for Use

The eligibility for using Sinutab Plus is strictly defined by regulatory documents, excluding specific patient groups due to pre-existing health conditions or concurrent medication use.

Eligibility Scope

Classification Population or Condition
Allowed Population Adults and children 12 years of age and over who do not have documented contraindications [DailyMed].
Contraindicated Children under 12 years of age are prohibited from using this medicine [SmPC].
Contraindicated Patients taking a Monoamine Oxidase Inhibitor (MAOI), or within 14 days of stopping MAOI therapy [DailyMed].
Contraindicated Individuals taking any other product containing Acetaminophen/Paracetamol (due to overdose risk) [DailyMed].
Contraindicated Patients with Severe Kidney Disease, Hypertension, Phaeochromocytoma, or Closed Angle Glaucoma [SmPC].
Conditional Use Patients with liver disease, heart disease, high blood pressure, diabetes mellitus, or thyroid disease must ask a health professional before use [DailyMed].
Not Recommended Pregnant and breastfeeding individuals [SmPC].

Connection to the Overall Eligibility Profile

The official eligibility profile is defined by absolute contraindications that protect users from cardiovascular risks associated with the decongestant component and overdose risks from Acetaminophen [SmPC]. This regulatory structure establishes the approved population as adults and adolescents aged 12 years and over who do not possess these documented severe risk factors or require professional consultation for conditions like diabetes or liver disease [DailyMed].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information defines specific drug–drug and drug–substance restrictions for Sinutab Plus, a fixed-dose combination of Acetaminophen and Phenylephrine.

Contraindicated Combinations and Restrictions

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is a formally documented contraindicated combination. This includes MAOI medicines such as Isocarboxazid, Phenelzine, and Linezolid, and the restriction applies for 14 days after stopping the MAOI. Use is also strictly restricted with any other product containing acetaminophen, which increases the overall risk of hepatotoxicity. Furthermore, the combination is generally restricted from co-use with other sympathomimetic decongestants to avoid additive effects.

Pharmacodynamic and Pharmacokinetic Interactions

The Phenylephrine component may reduce the efficacy of co-administered Beta-blockers and other antihypertensive medications, representing a documented pharmacodynamic antagonism. The co-formulation itself results in a pharmacokinetic interaction where the relative bioavailability and plasma concentration of Phenylephrine is increased. This exposure-modifying effect is noted as a potentially more significant risk for individuals with pre-existing cardiovascular conditions, such as hypertension.

Substance Interaction Restrictions

Daily alcohol consumption is advised to be avoided due to the officially documented increased risk of severe liver damage associated with the Acetaminophen component. Excessive intake of caffeine should also be avoided while using this product.

Mechanism of Action

The drug's mechanism involves a dual, non-overlapping action that targets two separate physiological pathways: central temperature control and peripheral vascular tone.

Central Modulation of Enzyme Systems

Acetaminophen acts primarily within the Central Nervous System ( CNS) by inhibiting Cyclooxygenase ( COX) enzyme isoforms in the hypothalamus. This inhibition results in a decrease of the mediator Prostaglandin E2 ( PGE2) synthesis. The resulting PGE2 signaling suppression resets the body's elevated thermal setpoint, which initiates heat loss mechanisms and results in a downward adjustment of core temperature. The mechanism also involves the modulation of central neural pathways related to nociception.

Peripheral Control of Sympathetic Receptors

Phenylephrine functions as a direct agonist on postsynaptic alpha1 -adrenergic receptors located on the small blood vessels within the nasal and sinus mucosa. Activating these receptors triggers the contraction of vascular smooth muscle, which decreases local blood flow and fluid leakage . This physiological effect results in a decrease in mucosal edema and an increase in the functional volume of the nasal cavity.

Mechanistic Limitations

The mechanism of Acetaminophen is largely constrained to the CNS and thus exhibits negligible anti-inflammatory action in peripheral tissues. The decongestant effect of Phenylephrine is strictly limited to vascular constriction and does not influence the production or viscosity of nasal secretions.

Dosage and Administration Information

Official Dosing and Administration Guidelines

Sinutab Plus, an oral fixed-dose combination containing Acetaminophen (325 mg) and Phenylephrine HCl (5 mg), is administered according to a strict, short-term usage protocol. The medicine is delivered exclusively via the oral route in the form of a caplet or tablet, which must be swallowed whole.


Standard Regimen and Frequency

The standard single dose for adults and pediatric patients 12 years of age and older is two caplets (a combination equivalent to 650 mg acetaminophen and 10 mg phenylephrine HCl). Doses are scheduled on an as-needed basis for temporary symptom relief, with a required minimum interval of four hours between each administration.


Maximum Intake and Duration Constraints

A critical procedural constraint limits the maximum intake to 10 caplets within any 24-hour period, a rule that simultaneously ensures the acetaminophen component does not exceed the recognized daily limit. The medicine is reserved for short-term use only: usage for pain or nasal congestion must not exceed seven consecutive days, while use for fever must not extend beyond three consecutive days.


Procedural and Population Rules

During administration, the caplet must not be crushed, chewed, or dissolved. Use in children under 12 years of age is not recommended without a doctor’s guidance. Furthermore, a core procedural rule requires that the product must not be taken concurrently with any other prescription or nonprescription medication containing acetaminophen. This restriction is essential to comply with the maximum daily dose constraint.

Recent Clinical Evidence

Sinutab Plus: Recent Clinical Evidence

Evidence for Overall Symptom Relief in Colds and Flu

Research has explored this medicine as a multi-symptom product for conditions characterized by functional limitations such as aches, fever, and nasal congestion, primarily focusing on adults and older children. The evidence comes mainly from systematic reviews and meta-analyses of randomized controlled trials (RCTs). These studies were designed to evaluate measured outcomes related to the full symptom cluster, including changes in measures of elevated body temperature and physical discomfort. While evidence quality varies across studies, some reviews have suggested that the documented changes in overall symptom scores were small. The findings describe group patterns observed in the studies, and results apply only to the populations studied.


Research on Temporary Relief of Nasal Congestion

The research base for the decongestant component, Phenylephrine, focuses on exploring outcomes related to nasal stuffiness in adults, using objective measures of nasal airflow alongside patient-reported outcomes. Findings were mixed across these trials, and research describes an area where evidence is limited. Importantly, the clinical function of the oral dose is an area under review. A major regulatory advisory committee review concluded that the current scientific data do not support the clinical value of the standard dosage as an oral nasal decongestant. This ongoing regulatory uncertainty means the data for this specific component are still emerging.


Foundational Studies and Research Gaps

Foundational pharmacokinetic studies in healthy adults found that the co-administration of acetaminophen was associated with a measured alteration in the systemic exposure of phenylephrine. These studies describe drug processing but do not report on clinical symptom relief. Data for young children (under the age of 6) are insufficient. A primary limitation is that follow-up durations were limited across the majority of efficacy trials, meaning long-term outcomes are not fully characterized in the research. The most significant gap is the ongoing regulatory uncertainty surrounding the clinical value of oral phenylephrine at the standard dose.

Frequently Asked Questions (FAQ)

Common questions about Sinutab Plus (FAQ)


Q: How quickly does Sinutab Plus start working for sinus pain?

A: According to official product information, the effects of the medicine may typically be felt within one hour after taking a dose. This timing is based on how quickly the body processes the active ingredients to begin relieving symptoms.


Q: How long does the effect of one dose of Sinutab Plus last?

A: The period of temporary symptom relief may last at least four hours. Dosing guidance advises waiting a minimum of four hours between administrations, which guides the typical duration of effect.


Q: Can I take Sinutab Plus to treat a headache not related to sinuses?

A: Yes, this medicine is classified as an analgesic (pain reliever) and is indicated for the relief of minor aches and pains, which generally includes headaches. The mechanism is designed to address general systemic discomfort.


Q: Can Sinutab Plus affect my blood pressure?

A: Official safety information notes that an increase in blood pressure (Hypertension) is a potential adverse effect associated with this medicine. Individuals with pre-existing high blood pressure are advised to consult a health professional before using this product. The decongestant component may also reduce the effectiveness of certain blood pressure medications.


Q: Does Sinutab Plus interact with common pain relievers like ibuprofen?

A: Regulatory labels contain a strict warning against taking this product with any other medication that contains acetaminophen (paracetamol). This is due to the risk of liver damage. There is no comparable, explicit restriction against common non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen.


Q: Can Sinutab Plus be taken at night?

A: Insomnia (trouble sleeping) is listed in official documents as a common adverse effect. This potential stimulant effect from the decongestant component means some warnings advise caution or avoiding use close to bedtime.


Q: What's the difference between Sinutab Plus and decongestants like Sudafed?

A: Sinutab Plus contains Phenylephrine as its active decongestant. Products with the original Sudafed formulation often contained Pseudoephedrine. These are different active ingredients, and the products have distinct pharmacological classifications.


Q: What are the signs that Sinutab Plus is starting to wear off?

A: As the medicine's effects diminish, the temporary symptoms it is treating—such as pain, fever, and congestion—may begin to return. Doses are typically scheduled based on the recurrence of these symptoms.


Q: What does it mean if Sinutab Plus doesn't help my symptoms?

A: Official labeling advises that if symptoms, such as pain or congestion, do not improve within seven days, use should be discontinued. Patients may review these directions in the product leaflet. Regulatory findings have noted limitations regarding the clinical value of the oral decongestant component.


Q: Are there any specific foods I should avoid while on Sinutab Plus?

A: Official documentation explicitly advises two substance restrictions: avoiding daily alcohol consumption due to the increased risk of severe liver damage associated with acetaminophen, and avoiding excessive intake of caffeine.


Q: Is it normal to have a dry mouth while taking Sinutab Plus?

A: Yes, official safety information lists dry mouth as a common adverse reaction associated with the medicine. This is a recognized side effect for some users.


Q: Can I take Sinutab Plus if I have a history of stomach issues?

A: Nausea is listed as a common adverse effect in official documentation. Official documentation advises that individuals with pre-existing conditions, such as severe kidney disease, should seek guidance from a health professional before using the product.


Q: Why do people sometimes say they feel energized after Sinutab Plus?

A: Nervousness and insomnia (trouble sleeping) are listed in official documents as common adverse effects. These effects are often associated with the sympathomimetic properties of the decongestant component, which can feel stimulating.


Q: Does Sinutab Plus help with a runny nose or just congestion?

A: The medicine is primarily indicated for the temporary relief of nasal congestion and pressure by reducing swelling. The combination is not specifically indicated to dry up a runny nose, an action typically provided by an antihistamine component.


Q: Is Sinutab Plus safe for people with a known allergy to paracetamol?

A: No. The product is strictly contraindicated (prohibited from use) for individuals who have demonstrated hypersensitivity or a severe allergic reaction to acetaminophen (paracetamol) or any other ingredients in the formulation.


Q: Can Sinutab Plus be used for an earache caused by sinus issues?

A: The medicine is indicated for the temporary relief of sinus congestion and pressure. Although the decongestant effect may help relieve pressure in the sinuses, it is not officially indicated for the treatment of an earache itself.


Q: Is it normal to feel a bit nauseous after taking the medicine?

A: Yes, official safety information lists nausea as a common adverse reaction associated with the medicine. This is a recognized side effect for some users.


Q: What are the ingredients that cause drowsiness in some sinus medications, and are they in Sinutab Plus?

A: Drowsiness in certain combination cold and flu products is typically caused by the inclusion of an antihistamine. Sinutab Plus does not contain the common sedating antihistamines found in some other cold/flu formulations.


Q: Is Sinutab Plus a good choice for allergic rhinitis?

A: While the primary indications are for general cold and flu symptoms, some product descriptions indicate that it may provide temporary relief from congestion associated with hay fever (allergic rhinitis).


Q: Can Sinutab Plus be used for a common cold without sinus symptoms?

A: Yes. The product is indicated for the temporary relief of aches, pain, and fever associated with the common cold, which means it can be taken even if nasal congestion is not a primary symptom.


Q: How does the decongestant in Sinutab Plus actually reduce swelling?

A: The decongestant component, Phenylephrine, works by causing the small blood vessels in the nasal passages to contract (vasoconstriction). This action shrinks the swollen tissue, reducing congestion and helping to open the airways.


Q: What kind of research has been done on Sinutab Plus for long-term safety?

A: Official information notes that most efficacy trials typically have limited follow-up durations. This means that long-term outcomes and safety considerations extending beyond short-term use are not fully characterized in the current research.


Q: Are there any age restrictions for purchasing Sinutab Plus?

A: The product is only for use by adults and children 12 years of age and older. While the product is generally sold over-the-counter, similar medicines containing certain other decongestants may be subject to legal restrictions regarding the age of the purchaser.


Q: Is the phenylephrine component in Sinutab Plus a stimulant?

A: Phenylephrine is classified as a sympathomimetic agent, meaning it affects the nervous system. Although not strictly a stimulant like caffeine, it can cause stimulant-like side effects, including nervousness and insomnia (trouble sleeping).


Q: What should I do if I miss a dose of Sinutab Plus?

A: The official documentation provides instructions regarding missed doses, which typically advise against taking a double dose. Users should refer to the product leaflet for guidance on resuming their regular schedule.


Q: Has there been much clinical research on the effectiveness of Sinutab Plus?

A: Clinical evidence exists from systematic reviews and meta-analyses. However, official information notes that the clinical value of the oral decongestant component at the standard dose is currently an area of ongoing regulatory review, suggesting some uncertainty regarding its efficacy.

How should Sinutab Plus be stored and disposed of?

How to Store and Dispose of Sinutab Plus

Storage of Sinutab Plus tablets must strictly follow regulatory mandates to ensure stability and safety. The medicine must be stored below 25 C and kept in the original packaging to protect it from light and moisture.

Official Requirements

Classification Regulatory Requirement
Temperature Limit Store below 25 C.
Protection Keep in original packaging/carton.
Child Safety Keep out of the sight and reach of children.
Disposal Dispose of unused product in accordance with local requirements.

Unused or expired product must not be thrown into household waste or flushed down the toilet. The stability of the medicine is maintained until the expiry date only if stored under these conditions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sinutab Plus found in:

A-Z Index: